AEA

AEA
Menu
Taiwan

Neurobit Technologies Co. Ltd.

【AEA 2018 Alumni】
Our mission
Neurobit is dedicated to providing a solution — A portable, wireless, eye movement/ nystagmus recording and analysis device (Neurospeed). When the medical imaging database established via artificial intelligence, we can make early detection and prediction to prevent the stroke and other brain diseases.

Company and management
Neurobit is headquartered and incorporated in Taipei City. The management of Neurobit consists of co-owners is listed below:

Name Title Background Speciality
Travis Yang CEO NTU-MSE PhD Biomedical Engineering and Biomaterials Design
Roger Chen COO & CFO FJCU-MGEM Marketing and Management
Jim Huang CTO & CDO NTU-BME MS Industrial and Mechanical Design
Ching-Fu Wang Technical Consultant NYMU-BME PhD Biomedical Data Science Analysis

In addition, we have assembled a board of advisors to provide management expertise. The advisors are:
Tzu-Pu Chang, M.D., Department of Neurology, Johns Hopkins University School of Medicine
Ke-Hung Chien, M.D., Oculofacial plastic and Orbital surgery, Ophthalmology, UCI Health Gavin Herbert Eye Institute
Tzu-Ming Liu, Ph.D., Associate Professor, Faculty of Health Sciences, University of Macau Chun-Yi Huang, Ph.D., Former TFDA Supervisory Medical Technologist

Our services
* Rapid Screening of Stroke and Brain Diseases
* Classification of Nerve Diseases
* Pre-treatment Evaluation & Post-treatment Monitoring

TRAVIS YANG
CEO

Nominated by

DON JYH-FU JENG – Taiwan
Chief Operating Officer,
Center for Industry Collaboration and Innovation Incubation, National Chengchi University
Neurobit is a pioneer in the field of medical diagnosis, which is an artificial intelligence system for stroke detection at very early stage, and to prevent many brain-related diseases. Stroke and brain diseases are missing effective methods for diagnosis and prevention. Such issues consume huge medical resources and cost. Neurobit develops a novel neuron detection method with artificial intelligence technology to diagnose the risk of stroke at the early stage, which will greatly reduce social costs and improve the quality of life.